Professor CHIU Ka Fung Peter    
趙家鋒

Assistant Dean (Translation & Entrepreneurship), Faculty of Medicine, CUHK
Professor, SH Ho Urology Centre, Department of Surgery, CUHK
MBChB (CUHK), PhD (EUR), FRCSEd (Urol), FCSHK, FHKAM (Surg)

Urology
(852) 3505 2625 / Appointment 3505 2954
peterchiuadd this for spam@add this for spamsurgery.cuhk.edu.hk
AAY-2052-2020
0000-0002-1499-8372

Biography

Dr Peter Chiu is currently an Associate Professor of the Chinese University of Hong Kong. He has primary interests in prostate cancer and benign prostatic hyperplasia. For prostate cancer, he has conducted studies in novel diagnostic modalities including blood biomarker prostate health index (phi), urine biomarker spermine, and transperineal MRI-Ultrasound fusion biopsy.

Dr Chiu was involved in the initiation of focal therapy service (HIFU and Cryotherapy) for prostate cancer in Hong Kong, and is the principal investigator of a phase 2 clinical trial on Targeted Microwave Ablation (TMA) for prostate cancer. For treatment of benign prostatic hyperplasia, he has conducted research in water vapour thermal therapy (REZUM), prostate artery embolization (PAE), Greenlaser vaporization (PVP), and Bluelaser vaporization. He has received research funding of US$ 23.7 million up to Jan 2026. He has published more than 215 articles in peer-reviewed journals including European Urology, European Urology Oncology, Journal of Urology, BJU International, and Prostate Cancer and Prostatic diseases.

Dr. Chiu was involved in the development of new robotic and therapeutic devices. He is the principal investigator of the first-in-human trial of Agilis Intilume system, an endoscopic robotic system with 2 flexible arms, for transurethral bladder surgery since 2024. He was also involved in the first-in-human trials of Da Vinci SP system (2017), Targeted Microwave Ablation (TMA) (first efficacy trial, 2019), Cornerstone Robotics (CSR) (2022) and Prostate Histotripsy (2026).

Research Interests

• Focal therapy for prostate cancer (Targeted Microwave Ablation [TMA], HIFU, Cryotherapy)
• Novel treatment for benign prostatic hyperplasia (REZUM, Urolift, Aquablation, Bluelaser vaporization, Microwave)
• Advanced robotic surgery for urological cancers (Da Vinci, Cornerstone Robotics, Agilis)
• Blood and urine biomarkers (prostate health index, urine Spermine risk score, etc) for prostate cancer
• Prostate cancer screening
• Transperineal MRI-Ultrasound fusion prostate biopsy

Additional Information

• President, Hong Kong Urological Association (2022-2026)
• Associate member, European Association of Urology (EAU) Prostate cancer guidelines panel
• Council member, Scientific Committee in Societe Internationale D'Urologie (SIU)
• Council member, Urological Association of Asia (UAA)
• Member, The EAU Young Academic Urologists Prostate cancer working group (2021-2024)
• Board Member, Focal Therapy Society
• Board Member, Hong Kong Kidney Foundation
• Editorial Board Member: Prostate cancer and Prostatic diseases, Asian Journal of Andrology
• Associate Editor: International Journal of Urology, Frontiers in Surgery (Genitourinary Surgery)

He is the principal investigator of:

1. SMART trial (NCT04685928)

• A multicentre randomized controlled trial in comparing MRI prostate pathway and extended transperineal prostate biopsy pathway in the diagnosis of significant prostate cancer
• https://clinicaltrials.gov/study/NCT04685928?term=chiu%20ka%20fung%20peter&page=2&rank=13

2. PROFUSION trial (NCT06303622)

• An international multicentre RCT to compare the linically significant prostate cancer (csPCa) detection of cognitive-guided and MRI-USG guided biopsies in men with suspicious MRI lesion. https://clinicaltrials.gov/study/NCT06303622?term=chiu%20ka%20fung%20peter&rank=10

3. Role of 18F PSMA PET for Prostate cancer diagnosis in equivocal MRI (NCT07386496)

• A multicentre RCT to compare MRI Vs MRI + PSMA PET in diagnosis of clinically significant prostate cancer in equivocal MRI
• https://clinicaltrials.gov/study/NCT07386496?term=chiu%20ka%20fung%20peter&rank=4

4. TMA-HK trial (NCT04113811)

• Targeted microwave ablation (TMA): The first efficacy trial for prostate cancer
• https://clinicaltrials.gov/study/NCT04113811?term=chiu%20ka%20fung%20peter&page=2&rank=14

5. VIOLETTA trial (NCT06262633)

• An international multicentre trial in the use of Targeted microwave ablation for prostate cancer
• https://clinicaltrials.gov/study/NCT06262633?term=chiu%20ka%20fung%20peter&rank=1

6. AI-assisted risk based prostate cancer detection (NCT05443412)

• https://clinicaltrials.gov/study/NCT05443412?term=chiu%20ka%20fung%20peter&rank=8

7. MRI prostate for Chinese men being screened for Prostate cancer

• The use of prostate health index and MRI for prostate cancer screening in Hong Kong as part of the CUHK Jockey club multi-cancer screening program.
• https://clinicaltrials.gov/study/NCT03891732?term=chiu%20ka%20fung%20peter&page=2&rank=12

8. BETTY trial (NCT05443451)

• First-in-human trial of Transperineal Targeted microwave ablation (TMA) for Benign prostatic hyperplasia
• https://clinicaltrials.gov/study/NCT05443451?term=chiu%20ka%20fung%20peter&rank=6

9. REZUM-TURP RCT (NCT05762198)

• RCT comparing REZUM and TURP for men with BPH and refractory retention
• https://clinicaltrials.gov/study/NCT05762198?term=chiu%20ka%20fung%20peter&rank=7

10. REZUM-Urolift RCT (NCT06820606)

• RCT comparing REZUM and Urolift for men with BPH
• https://clinicaltrials.gov/study/NCT06820606?term=chiu%20ka%20fung%20peter&page=1&rank=3

11. WOLVERINE trial (NCT07214675)

• First-in-human Prostate histotripsy for treating BPH
• PI in Hong Kong
• https://clinicaltrials.gov/study/NCT07214675?term=prostate%20histotripsy&rank=1

Selected Publications

1. Chiu PK, Liu AQ, Yee CH, Wong HF, Chan CH, Kong A, Lau SY, Teoh JY, Lo KL, Yuen TY, Wong KH, Chu CM, Hung HY, Cho CC, Ng CF. Targeted Microwave Ablation for Prostate Cancer Under Magnetic Resonance Imaging-Ultrasound Fusion and Organ-based Tracking: Final Results from the First Phase 2 Trial (TMA-HK). Eur Urol Oncol. 2025 Apr;8(2):253-257.
2. Yee CH, Chiu PK, Tay KJ, Tan YG, Wong HF, Siu B, Nicoletti R, Teoh JY, Ng CF. Cryotherapy for posterior lesions of the prostate: the hydrogel technique. BJU Int. 2025 May;135(5):869-873. (co-corresponding author)
3. Chiu PK, Liu AQ, Lau SY, Teoh JY, Ho CC, Yee CH, Hou SM, Chan CK, Tang WL, Bangma CH, Chu PS, Poon WT, Ng CF, Roobol MJ. A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort. BJU Int. 2025 Jan;135(1):71-77.
4. Peng Q, Chen Y, Xie T, Pu D, Ho VW, Sun J, Liu K, Chan RC, Ding X, Teoh JY, Wang X, Chiu PK, Ng CF. PiRNA-4447944 promotes castration-resistant growth and metastasis of prostate cancer by inhibiting NEFH expression through forming the piRNA-4447944-PIWIL2-NEFH complex. Int J Biol Sci. 2024 Jul 1;20(9):3638-3655. (Co-corresponding author)
5. Chiu PK, Leow JJ, Chiang CH, Mok A, Zhang K, Hsieh PF, Zhu Y, Lam W, Tsang WC, Fan YH, Lin TP, Chan TY, Leung CH, Teoh JY, Chu PS, Zhu G, Ye DW, Wu HC, Tan TW, Tsu JH, Ng CF, Chiong E, Huang CY. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation. J Urol. 2023 Jul;210(1):88-98.
6. Chiu PK, Kasivisvanathan V, Gandaglia G; European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Prostate Biopsy. Eur Urol. 2023 Apr 24:S0302-2838(23)02730-6.
7. He BM, Chiu PK, Tao T, Lan JH, Cai JT, Zhou SC, Li RB, Ren Y, Ka-Lun LO, Xu RY, Chen JR, Lan D, Gao JL, Chu SG, Jin ZC, Huang FF, Shi ZK, Yang QW, Zhou H, Wang SD, Ji TR, Han QP, Wang CM, Chi-Fai NG, Wang HF; APROPOS Group. Perineal nerve block versus periprostatic block for patients undergoing transperineal prostate biopsy (APROPOS): a prospective, multicentre, randomised controlled study. EClinicalMedicine. 2023 Mar 23;58:101919.
8. Chiu PK, Chan CH, Yee CH, Lau SY, Teoh JY, Wong HF, Lo KL, Yuen TY, Hung HY, Cho CC, Ng CF. Transperineal Targeted Microwave Ablation (TMA) of localized prostate cancer guided by MRI-Ultrasound fusion and organ-based tracking: a pilot study. Prostate Cancer Prostatic Dis. 2022 Jul 14.
9. Chiu PK, Shen X, Wang G, Ho CL, Leung CH, Ng CF, Choi KS, Teoh JY. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):672-676.
10. Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, Yee CH, Teoh JY, Hou SM, Roobol M, Ng CF, Chiu PK. Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study. Prostate Cancer Prostatic Dis. 2021 Aug 27.
11. Chiu PK, Fung YH, Teoh JY, Chan CH, Lo KL, Li KM, Tse RT, Leung CH, Wong YP, Roobol MJ, Wong KL, Ng CF. Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):542-548.
12. Luiting HB, Remmers S, Boevé ER, Valdagni R, Chiu PK, Semjonow A, Berge V, Tully KH, Rannikko AS, Staerman F, Roobol MJ. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study. Eur Urol Oncol. 2022 Apr 15:S2588-9311(22)00057-8.
13. Zhu Y, Wei Y, Zeng H, Li Y, Ng CF, Zhou F, He C, Sun G, Ni Y, Chiu PKF, Teoh JYC, Wang B, Pan J, Wan F, Dai B, Qin X, Lin G, Gan H, Wu J, Ye D. Inherited Mutations in Chinese Men With Prostate Cancer. J Natl Compr Canc Netw. 2021 Oct 15;20(1):54-62.
14. Chiu PK, Lo KL, Teoh JY, Ma SF, Leung CH, Wong HF, Li KM, Sae-Lo K, Kwok SW, Li SY, Yee CH, Hou SM, Ng CF. Sectoral cancer detection and tolerability of freehand transperineal prostate biopsy under local anaesthesia. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):431-438. doi: 10.1038/s41391-020-00293-1.
15. Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol. 2019 Apr;75(4):558-561.
16. Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, Tijsterman JD, Beerlage HP, Mannaerts CK, Schimmöller L, Albers P, Arsov C. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Eur Urol. 2019 Feb;75(2):310-318.
17. Chiu PK, Alberts AR, Venderbos LDF, Bangma CH, Roobol MJ. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. BJU Int. 2017 Sep;120(3):394-400.
18. Chiu PK, Roobol MJ, Nieboer D, Teoh JY, Yuen SK, Hou SM, Yiu MK, Ng CF. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population. Prostate Cancer Prostatic Dis. 2017 Mar;20(1):99-104.